Negative pigment network able to distinguish melanoma

October 25, 2012
Negative pigment network able to distinguish melanoma
Negative pigment network can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Academy of Dermatology.

(HealthDay)—Negative pigment network (NPN) can be used to distinguish melanoma from Spitz nevus and other benign lesions, according to a study published online Oct. 11 in the Journal of the American Academy of Dermatology.

Maria A. Pizzichetta, M.D., from the in Aviano, Italy, and colleagues assessed the frequency, sensitivity, specificity, and odds of NPN in digitalized images of from 679 patients with histopathological diagnosis of dermatofibroma (115), melanocytic nevus (220), Spitz nevus (139), and (205).

The researchers found that the frequency of NPN was higher in the melanoma group (34.6 percent) than in the Spitz nevus (28.8 percent), melanocytic nevus (18.2 percent), and dermatofibroma (11.3 percent) groups. The odds of melanoma diagnosis versus non-melanoma diagnosis in the presence of NPN were significantly increased (odds ratio, 1.8). For melanocytic nevi and dermatofibromas, the odds ratios were very low (0.5 and 0.3, respectively), while for Spitz nevi, the odds ratio of 1.1 was not statistically significant. There was a significantly higher frequency of multicomponent pattern (68.1 percent), asymmetric pigmentation (92.9 percent), irregularly distributed NPN (87.3 percent), and peripheral location of NPN (66.2 percent) in melanomas compared to dermatofibroma, melanocytic nevus, and Spitz nevus.

"The overall morphologic pattern of NPN, such as the irregular distribution and the peripheral location of NPN, along with the multicomponent pattern and the asymmetric pigmentation could be used as additional features in distinguishing melanoma from Spitz nevus and other ," the authors write.

Explore further: Pathologists tend to reclassify prior nonmalignant diagnoses

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pathologists tend to reclassify prior nonmalignant diagnoses

August 17, 2012
(HealthDay) -- For dermatopathologists there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the ...

Accuracy of melanoma detection up in specialized clinics

June 21, 2012
(HealthDay) -- From 1998 to 2007, the accuracy of melanoma detection improved in specialized but not non-specialized clinical settings, according to research published in the July issue of the Journal of the American Academy ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.